Cited 18 times in
Combined treatment of 3-hydroxyflavone and imatinib mesylate increases apoptotic cell death of imatinib mesylate-resistant leukemia cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 구본녀 | - |
dc.date.accessioned | 2014-12-19T17:26:05Z | - |
dc.date.available | 2014-12-19T17:26:05Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0145-2126 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/91401 | - |
dc.description.abstract | Imatinib mesylate, a Bcr/Abl tyrosine kinase inhibitor, is widely used in treating chronic myeloid leukemia. However, drug-resistance of leukemia cells becomes an emergent problem. Herein, various flavonoids were screened for applicability in leukemia treatment, and 3-hydroxyflavone (3-HF) was found to be most effective in reducing cancer cell viability. The combination of 3-HF and imatinib mesylate resulted in significant apoptotic cell death in imatinib mesylate-resistant leukemia cells. Combined treatment resulted in apparent activation of caspases and decrease of the oncoprotein phosphor-Bcr/Abl in leukemia cells. Our results suggest that this combined treatment is beneficial in imatinib mesylate-resistant chronic myelogenous leukemia. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | LEUKEMIA RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Combined treatment of 3-hydroxyflavone and imatinib mesylate increases apoptotic cell death of imatinib mesylate-resistant leukemia cells | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Anesthesiology (마취통증의학) | - |
dc.contributor.googleauthor | Jung-Hyun Kim | - |
dc.contributor.googleauthor | Minjung Song | - |
dc.contributor.googleauthor | Geun-Ho Kang | - |
dc.contributor.googleauthor | Eung-Ryoung Lee | - |
dc.contributor.googleauthor | Hye-Yeon Choi | - |
dc.contributor.googleauthor | Chung Lee | - |
dc.contributor.googleauthor | Jin-Hoi Kim | - |
dc.contributor.googleauthor | Youngsoo Kim | - |
dc.contributor.googleauthor | Bon-Nyeo Koo | - |
dc.contributor.googleauthor | Ssang-Goo Cho | - |
dc.identifier.doi | 10.1016/j.leukres.2012.05.018 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00193 | - |
dc.relation.journalcode | J02166 | - |
dc.identifier.eissn | 1873-5835 | - |
dc.identifier.pmid | Chronic myelogenous leukemia (CML) ; Flavonoid ; 3-Hydroxyflavone ; Imatinib mesylate-resistant cells ; Phosphor-Bcr/Abl ; Apoptosis | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0145212612002433 | - |
dc.subject.keyword | Chronic myelogenous leukemia (CML) | - |
dc.subject.keyword | Flavonoid | - |
dc.subject.keyword | 3-Hydroxyflavone | - |
dc.subject.keyword | Imatinib mesylate-resistant cells | - |
dc.subject.keyword | Phosphor-Bcr/Abl | - |
dc.subject.keyword | Apoptosis | - |
dc.contributor.alternativeName | Ku, Bon Nyo | - |
dc.contributor.affiliatedAuthor | Ku, Bon Nyo | - |
dc.citation.volume | 36 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 1157 | - |
dc.citation.endPage | 1164 | - |
dc.identifier.bibliographicCitation | LEUKEMIA RESEARCH, Vol.36(9) : 1157-1164, 2012 | - |
dc.identifier.rimsid | 31257 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.